Octapharma USA, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new 2-gram presentation ...

DUBLIN--(BUSINESS WIRE)--The "Fibrinogen Deficiency (Factor I Deficiency) Ongoing Global Clinical Trials Analysis and Outlook" report has been added to ResearchAndMarkets.com's offering. Fibrinogen ...

Fibrinogen plays an important role in coagulation and blood clotting in emergency and surgical settings. Fibrinogen is the first coagulation factor to drop to critically low levels during severe ...

Fesilty is expected to be available in the first half of 2026. The Food and Drug Administration (FDA) has approved Fesilty ™ (fibrinogen, human-chmt) for the treatment of acute bleeding episodes in ...

January 28, 2009 — On January 16, the US Food and Drug Administration (FDA) granted accelerated approval to human fibrinogen concentrate (RiaSTAP, CSL Behring). This orphan drug is intended for use in ...

Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate 14.02.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/wp5429/analysis_of_the) has announced the addition of the "Analysis of the ...

Dreieich, 7 April 2020. Biotest AG announces today that the first patient with pseudomyxoma peritonei (PMP) has been treated as part of the ongoing phase III trial for the treatment of severe bleeding ...

Octapharma has announced the publication of new data demonstrating that the fibrinogen concentrate fibryga ® is an effective alternative to cryoprecipitate for patients with severe bleeding during ...

A new study from the University of Alberta demonstrated that the blood clotting protein called fibrinogen also regulates MMP-2, an enzyme involved in immunity and in clot formation inside blood ...